Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy

• US 8,354,228 B2
• Filed: 12/07/2009
• Issued: 01/15/2013
• Est. Priority Date: 10/11/2004
• Status: Expired due to Fees

• Current Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD.
• Original Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD.
• Inventors: Ron, Dina
• Primary Examiner(s): AEDER, SEAN E
• Application Number:
  US12/591,960
• Publication Number:
  US 20100093840A1
• Time in Patent Office: 1,135 Days
• Field of Search: None
• US Class Current: 435/6.1
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/21 containing a His-tag
• CPC Class Codes: C07K 2319/41 containing a Myc-tag

Abstract

A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion being capable of inhibiting RTK-mediated cell proliferation. Also provided are methods and kits for diagnosing and staging of cancer by detecting the expression level of hSef in a tissue sample, wherein a decrease in hSef expression level is indicative of cancer.

Claims

1. A method of diagnosing thyroid cancer or prostate cancer in a subject in need thereof, the method comprising:

(a) detecting in a thyroid or prostate tissue sample of the subject, respectively an expression level of a Sef polynucleotide which is hybridizable to SEQ ID NO;

31, wherein a decrease in said expression level of said Sef polynucleotide in said tissue sample as compared to said expression level of said Sef polynucleotide in a corresponding unaffected or normal tissue is indicative of the presence of the thyroid or prostate cancer, respectively; and

(b) determining a malignancy of said cancer based on said decrease in said expression level, wherein a reduced expression of said Sef polynucleotide in said thyroid or prostate tissue sample correlates with an increase in said malignancy of the thyroid or prostate cancer, respectively, and

(c) classifying patients with reduced expression of said Sef polynucleotide in said prostate tissue or in said thyroid tissue as having prostate cancer or thyroid cancer, respectively,

thereby diagnosing the thyroid cancer or prostate cancer, respectively, in the subject in need thereof.

2. The method of claim 1, wherein said detecting is effected by an RNA detection method.

3. The method of claim 2, wherein said RNA detection method is selected from the group consisting of RNA in situ hybridization, RT-PCR, in situ RT-PCR and Northern blot analysis.

4. The method of claim 1, wherein said cancer is a primary solid tumor.

8. The method of claim 1, further comprising selecting a treatment regimen based on said diagnosing.

5. A method of selecting a treatment regimen for a subject having thyroid carcinoma or prostate cancer, the method comprising:

(a) detecting in a thyroid or prostate tissue sample of the subject, respectively an expression level of a Sef polynucleotide which is hybridizable to SEQ ID NO;

31, wherein a decrease in said expression level of said Sef polynucleotide in said tissue sample as compared to said expression level of said Sef polynucleotide in a corresponding unaffected or normal tissue is indicative of the presence or malignancy of the thyroid or prostate cancer, respectively; and

(b) classifying patients with reduced expression of said Sef polynucleotide in said prostate tissue or in said thyroid tissue as having prostate cancer or thyroid cancer, respectively, and

(c) selecting an anti-cancer therapy regimen based on said presence or said malignancy of the thyroid or prostate cancer, respectively,

thereby selecting the treatment regiment for the subject.

6. A method of diagnosing thyroid carcinoma or prostate cancer in a subject in need thereof, the method comprising:

(a) determining a presence of a cancer diagnostic marker in a thyroid or prostate tissue sample of the subject, respectively, and;

(b) detecting in said thyroid or prostate tissue sample an expression level of a Sef polynucleotide which is hybridizable to SEQ ID NO;

31, and

(c) classifying patients with reduced expression of said Sef polynucleotide in said prostate tissue or in said thyroid tissue as having prostate cancer or thyroid cancer, respectively,

wherein said decrease in said expression level of said Sef correlates with an increased malignancy and/or aggressiveness of said thyroid or prostate cancer, respectively,

thereby diagnosing the thyroid carcinoma or prostate cancer, respectively, in the subject in need thereof.

7. The method of claim 6, further comprising selecting a treatment regimen based on said diagnosis.

9. A method of determining a prognosis of a subject having cancerous solid tumor selected from the group consisting of thyroid carcinoma and prostate cancer, comprising:

(a) selecting a subject diagnosed with the cancerous solid tumor, and;

(b) detecting in a sample of the cancerous solid tumor an expression level of a Sef polynucleotide which is hybridizable to SEQ ID NO;

31,

wherein a complete loss of said expression level of said Sef polynucleotide in said sample is indicative of a poor prognosis, and

(c) classifying patients with said complete loss of expression level of said Sef polynucleotide in said prostate tissue or in said thyroid tissue as having poor prognosis, respectively,

thereby determining the prognosis of the subject having cancerous solid tumor.

10. The method of claim 9, wherein said poor prognosis is associated with a malignant, aggressive and/or metastatic cancer.

11. A method of selecting a treatment regimen for a subject having a skin cancer, the method comprising:

(a) detecting in a skin cancer tissue sample of the subject, an expression level of a Sef polynucleotide which is hybridizable to SEQ ID NO;

31, wherein a decrease in said expression level of said Sef polynucleotide in said skin cancer tissue sample as compared to said expression level of said Sef polynucleotide in a corresponding unaffected or normal tissue is indicative of the presence of the skin cancer; and

(b) selecting an anti-cancer therapy regimen based on said presence of the skin cancer,

thereby selecting the treatment regiment for the subject.

12. The method of claim 11, wherein said skin cancer is melanoma.

13. A method of diagnosing skin cancer in a subject in need thereof, the method comprising:

(a) determining a presence of a cancer diagnostic marker in a skin tissue sample of the subject, respectively, and;

(b) detecting in said skin tissue sample an expression level of a Sef polynucleotide which is hybridizable to SEQ ID NO;

31,

wherein said presence of said cancer diagnostic marker in said tissue in combination with a decrease in said expression level of said Sef polynucleotide in said tissue sample as compared to said expression level of said Sef polynucleotide in a corresponding unaffected or normal tissue is indicative of a diagnosis of the cancer,

(c) classifying patients with reduced expression of said Sef polynucleotide in said skin tissue as having skin cancer,

thereby diagnosing the skin cancer, respectively, in the subject in need thereof.

14. The method of claim 13, further comprising selecting a treatment regimen based on said diagnosing.